263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 84
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 1.2M | 1.26M | 1964 |
Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 56.72k | N/D | 1967 |
Mr. Michael Breininger CPA, M.B.A. | Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller | N/D | N/D | 1982 |
Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | N/D | N/D | 1983 |
John Kouch J.D. | General Counsel | N/D | N/D | N/D |
Ms. Tiffany J. Hamilton M.B.A. | Head of Corporate Communications | N/D | N/D | N/D |
Mr. Michael Shine M.B.A. | Senior Vice President of Commercial | N/D | N/D | N/D |
Ms. Jyothy Pillai M.S. | Head of Regulatory & Quality | N/D | N/D | N/D |
Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer | N/D | N/D | N/D |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
La calificación ISS Governance QuickScore de Ocugen, Inc. a partir del 1 de marzo de 2024 es 9. Las puntuaciones principales son Auditoría: 5; Junta: 7; Derechos del accionista: 8; Compensación: 10.